Related references
Note: Only part of the references are listed.Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir
Kai S. Yang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CLpro
Ling Ma et al.
ANTIVIRAL RESEARCH (2022)
Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2viaintegrated computational approach
Salman Ali Khan et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2021)
Elucidating biophysical basis of binding of inhibitors to SARS-CoV-2 main protease by using molecular dynamics simulations and free energy calculations
Md Fulbabu Sk et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2021)
A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2
Alexander Simonis et al.
EMBO MOLECULAR MEDICINE (2021)
What coronavirus 3C-like protease tells us: From structure, substrate selectivity, to inhibitor design
Muya Xiong et al.
MEDICINAL RESEARCH REVIEWS (2021)
An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19
Dafydd R. Owen et al.
SCIENCE (2021)
Corilagin inhibits SARS-CoV-2 replication by targeting viral RNA-dependent RNA polymerase
Quanjie Li et al.
ACTA PHARMACEUTICA SINICA B (2021)
The origins of SARS-CoV-2: A critical review
Edward C. Holmes et al.
CELL (2021)
Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations
Bilal Ahmad et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development
Miao-Miao Zhao et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Rational design and Structure-Activity relationship of coumarin derivatives effective on HIV-1 protease and partially on HIV-1 reverse transcriptase
Mei Zhu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Preliminary SAR and biological evaluation of potent HIV-1 protease inhibitors with pyrimidine bases as novel P2 ligands to enhance activity against DRV-resistant HIV-1 variants
Mei Zhu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Synthesis and evaluation of potent human immunodeficiency virus 1 protease inhibitors with epimeric isopropanol as novel P1′ ligands
Mei Zhu et al.
FUTURE MEDICINAL CHEMISTRY (2020)
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
Roujian Lu et al.
LANCET (2020)
Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
Guangdi Li et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms
Bodee Nutho et al.
BIOCHEMISTRY (2020)
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
Wenhao Dai et al.
SCIENCE (2020)
Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors
Linlin Zhang et al.
SCIENCE (2020)
Novel HIV-1 Protease Inhibitors with Morpholine as the P2 Ligand to Enhance Activity against DRV-Resistant Variants
Mei Zhu et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds
Anh-Tien Ton et al.
MOLECULAR INFORMATICS (2020)
Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
Zhenming Jin et al.
NATURE (2020)
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19
B. Cao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Design and biological evaluation of novel HIV-1 protease inhibitors with isopropanol as P1′ ligand to enhance binding with S1′ subsite
Mei Zhu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2020)
Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening
Olga Abian et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2020)
Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
Mahmoud Kandeel et al.
LIFE SCIENCES (2020)
Efficacy of Lopinavir/Ritonavir Compared With Standard Care for Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review
Timotius Ivan Hariyanto et al.
Infectious Disorders - Drug Targets (2020)
Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses
Zeinab Abdelrahman et al.
FRONTIERS IN IMMUNOLOGY (2020)
A pneumonia outbreak associated with a new coronavirus of probable bat origin (vol 579, pg 270, 2020)
Peng Zhou et al.
NATURE (2020)
Synthesis and biological evaluation of new HIV-1 protease inhibitors with purine bases as P2-ligands
Mei Zhu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Design, synthesis and biological evaluation of novel HIV-1 protease inhibitors with pentacyclic triterpenoids as P2-ligands
Mei Zhu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Origin and evolution of pathogenic coronaviruses
Jie Cui et al.
NATURE REVIEWS MICROBIOLOGY (2019)
Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element
Anushka C. Galasiti Kankanamalage et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir
Manabu Aoki et al.
JOURNAL OF VIROLOGY (2016)
Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial
C. Orkin et al.
HIV MEDICINE (2013)
Share Paper
